Skip to main content

AstraZeneca COVID-19 vaccine shows 74% efficacy in large US trial

AstraZeneca’s COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65 and older, according to long-awaited results of the company’s US clinical trial published on Wednesday.

Overall efficacy of 74% was lower than the interim 79% figure reported by the British drugmaker in March, a result AstraZeneca revised days later to 76% after a rare public rebuke from health officials that the figure was based on “outdated information.”

The data looked at more than 26,000 volunteers in the United States, Chile and Peru, who received two doses of the vaccine spaced about a month apart. The results were published in the New England Journal of Medicine.

There were no cases of severe or critical symptomatic COVID-19 among the more than 17,600 participants who got the vaccine, compared with 8 such cases among the 8,500 volunteers who got the placebo. There were also two deaths in the placebo group but none among those who received the vaccine.

“I was pleasantly surprised,” Dr. Anna Durbin, a vaccine researcher at Johns Hopkins University and one of the study’s investigators, said of the overall result. “It was also highly protective against severe disease and hospitalization,” she said.

There were no cases of a rare but serious blood clotting side effect called thrombosis with thrombocytopenia that has been linked to the AstraZeneca vaccine developed with Oxford University researchers.

AstraZeneca said in late July it planned to file for full approval with the U.S. Food and Drug Administration, rather than seek emergency use authorization. Chief Executive Pascal Soriot told a media briefing at the time he hoped the vaccine could still play a role in the United States, even though the process was taking longer than expected.

The company is exploring booster doses for people whohave already been vaccinated with two doses of either its ownshot or mRNA-based vaccines from Pfizer/BioNTech or Moderna.

The vaccine, known as Vaxzevria, is authorized for use in more than 170 countries. A spokesperson said the company expects to file for U.S. approval later this year.

Durbin said she does not expect Vaxzevria to be used much in the United States, but securing FDA approval “does give them gravitas.”

Facebook Notice for EU! You need to login to view and post FB Comments!

The post AstraZeneca COVID-19 vaccine shows 74% efficacy in large US trial appeared first on ARY NEWS.



from ScienceTechnology – ARY NEWS https://ift.tt/2YaCOqQ https://ift.tt/eA8V8J

from TechCrunch https://ift.tt/3usnZMj
via IFTTT
Labels:

Comments

Post a Comment

Popular posts from this blog

The Silent Revolution of On-Device AI: Why the Cloud Is No Longer King

Introduction For years, artificial intelligence has meant one thing: the cloud. Whether you’re asking ChatGPT a question, editing a photo with AI tools, or getting recommendations on Netflix — those decisions happen on distant servers, not your device. But that’s changing. Thanks to major advances in silicon, model compression, and memory architecture, AI is quietly migrating from giant data centres to the palm of your hand. Your phone, your laptop, your smartwatch — all are becoming AI engines in their own right. It’s a shift that redefines not just how AI works, but who controls it, how private it is, and what it can do for you. This article explores the rise of on-device AI — how it works, why it matters, and why the cloud’s days as the centre of the AI universe might be numbered. What Is On-Device AI? On-device AI refers to machine learning models that run locally on your smartphone, tablet, laptop, or edge device — without needing constant access to the cloud. In practi...
1 comment
Read more

Apple’s AI Push: Everything We Know About Apple Intelligence So Far

Apple’s WWDC 2025 confirmed what many suspected: Apple is finally making a serious leap into artificial intelligence. Dubbed “Apple Intelligence,” the suite of AI-powered tools, enhancements, and integrations marks the company’s biggest software evolution in a decade. But unlike competitors racing to plug AI into everything, Apple is taking a slower, more deliberate approach — one rooted in privacy, on-device processing, and ecosystem synergy. If you’re wondering what Apple Intelligence actually is, how it works, and what it means for your iPhone, iPad, or Mac, you’re in the right place. This article breaks it all down.   What Is Apple Intelligence? Let’s get the terminology clear first. Apple Intelligence isn’t a product — it’s a platform. It’s not just a chatbot. It’s a system-wide integration of generative AI, machine learning, and personal context awareness, embedded across Apple’s OS platforms. Think of it as a foundational AI layer stitched into iOS 18, iPadOS 18, and m...
Post a Comment
Read more

Billionaire clothing dynasty heiress launches Everybody & Everyone to make fashion sustainable

Veronica Chou’s family has made its fortune at the forefront of the fast fashion business through investments in companies like Michael Kors and Tommy Hilfiger . But now, the heiress to an estimated $2.1 billion fortune is launching her own company, Everybody & Everyone , to prove that the fashion industry can be both environmentally sustainable and profitable. There’s no argument about the negative impacts of the fashion industry on the environment. The textiles industry primarily uses non-renewable resources — on the order of 98 million tons per year. That includes the oil to make synthetic fibers, fertilizers to grow cotton, and toxic chemicals to dye, treat, and produce the textiles used to make clothes. The greenhouse gas footprint from textiles production was roughly 1.2 billion tons of CO2 equivalent in 2015 — more than all international flights and maritime shipments combined (and a lot of those maritime shipments and international flights were hauling clothes). The lit...
Post a Comment
Read more